Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (281-290 of 298) with videos related to

Pageof 30
Sort By:
JHEP Reports : Innovation in Hepatology|May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILIMar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Revista Espanola De Enfermedades Digestivas|December 14, 2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liverJoaquín Cabezas, Javier Crespo, Antonio Aguilera, et al.
Hepatology (Baltimore, Md.)|July 30, 2024
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Journal of Hepatology|January 8, 2025
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)Edo J Dongelmans, Grishma Hirode, Bettina E Hansen, et al.
Hepatology (Baltimore, Md.)|January 16, 2025
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Journal of Hepatology|September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cureGeorg Semmler, Sabela Lens, Elias L Meyer, et al.
Journal of Hepatology|March 23, 2024
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2017
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4Zoe Mariño, Juan M Pascasio-Acevedo, Adolfo Gallego, et al.
Journal of Clinical Microbiology|November 8, 2014
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsJosep Quer, Josep Gregori, Francisco Rodríguez-Frias, et al.
Pageof 30

Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
JHEP Reports : Innovation in Hepatology|May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILIMar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Revista Espanola De Enfermedades Digestivas|December 14, 2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liverJoaquín Cabezas, Javier Crespo, Antonio Aguilera, et al.
Hepatology (Baltimore, Md.)|July 30, 2024
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Journal of Hepatology|January 8, 2025
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)Edo J Dongelmans, Grishma Hirode, Bettina E Hansen, et al.
Hepatology (Baltimore, Md.)|January 16, 2025
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Journal of Hepatology|September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cureGeorg Semmler, Sabela Lens, Elias L Meyer, et al.
Journal of Hepatology|March 23, 2024
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2017
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4Zoe Mariño, Juan M Pascasio-Acevedo, Adolfo Gallego, et al.
Journal of Clinical Microbiology|November 8, 2014
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsJosep Quer, Josep Gregori, Francisco Rodríguez-Frias, et al.
Pageof 30